Tim Smith

In this analysis, the 12-month use of a home-use helmet-type LLLT device was evaluated among individuals with androgenetic alopecia (AGA).

In this post hoc analysis, investigators used phase 3 data on vunakizumab to investigate the impact of early response on long-term efficacy in those with psoriasis.

Jasper Therapeutics has released new, positive findings on the use of briquilimab, a novel antibody therapy targeting KIT (CD117), in patients with CSU.

This study evaluated the drug survival of different biologic therapies for patients with psoriasis in a routine clinical practice setting.

Investigators look at the ways in which CSU impacts family members supporting those with CSU, using the Family Dermatology Life Quality Index (FDLQI).

This study highlights the efficacy and safety of deucravacitinib 6 mg in psoriasis, with results stratified by body mass index and age in a Japanese patient cohort.

Two phase 3 trials met their primary and secondary endpoints in patients with moderate-to-severe plaque psoriasis on envudeucitinib.

This quarterly recap highlights some of the most notable news and developments in the dermatology space from Q4 in 2025.

Investigators observed disparities in race with persistent chemotherapy-induced alopecia among women with breast cancer.

This summary of headlines in the field of dermatology summarizes some of the most notable news covered in December 2025.

The data may help to guide informed decision-making related to dupilumab use and management of severe atopic dermatitis in infants and young children.

Investigators conducted a network meta-analysis comparing and ranking the safety and efficacy of dietary supplements as adjunctive therapy for patients with psoriasis.

Investigators explored the measurement properties of the Patient-Reported Outcomes Measurement Information System (PROMIS) among patients with chronic skin disease.

In this end-of-year reel, HCPLive has showcased several key highlights from the Skin of Color Savvy podcast in 2025.

Catch up on news headlines highlighted in the dermatology space by HCPLive in 2025 with this Year in Review.

Catch up on some of the biggest alopecia areata news headlines covered by HCPLive from 2025 with this ‘Year in Review’ summary.

To stay informed, catch up on some of the most notable alopecia areata news headlines from 2025 with our Year in Review.

Catch up on some of the most significant headlines in atopic dermatitis news coverage from 2025 with our Year in Review.

Catch up on some of the most notable headlines in psoriasis news coverage from 2025 with our Year in Review.

In this analysis, investigators assessed the effects of any weight-loss intervention, behavioural or pharmacological, on the severity of psoriasis as well as quality-of-life outcomes.

This study explored the potential impact of body mass index (BMI) and smoking on patients’ risk of developing hidradenitis suppurativa.

In a new post hoc analysis of 4 pivotal clinical studies in atopic dermatitis and prurigo nodularis, nemolizumab was shown to improve symptoms.

Investigators observed rapid, sustained clinical benefits after using vixarelimab in patients living with prurigo nodularis.

Topline findings from the phase 2b REZOLVE-AA trial highlight the efficacy of rezpegaldesleukin in severe-to-very-severe alopecia areata.

Investigators highlighted patterns of addictive behavior among those with chronic skin diseases in European tertiary dermatology centers.

Prurigo nodularis was shown to be linked with a significantly increased risk of malignancy, especially with cutaneous cancers.

Vanda Pharmaceuticals submitted a BLA to the FDA for imsidolimab, a novel IgG4 IL-36 receptor antagonist, to treat generalized pustular psoriasis (GPP).

Investigators compared the 2-year drug survival rates of biologics and JAKi in atopic dermatitis, in addition to evaluating associated predictors.

In this survey, investigators evaluated patients’ comprehension of frequently used cutaneous oncology-related words and looked at factors impacting their comprehension.

The phase 3 DISCREET study explored the safety and efficacy of apremilast in treating patients with moderate to severe genital psoriasis over 32 weeks.